SCHEMBL5539803

SCHEMBL5539803

CC(C)(C)OC(=O)N1CCN(C(=O)OC[C@](C)(O)Cn2cc([N+](=O)[O-])nc2Cl)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.42
LMNA P02545 2/20 0.42
MAPT P10636 2/20 0.42
POLB P06746 1/20 0.39
KCNH2 Q12809 1/20 0.38
HTT P42858 1/20 0.36
ATM Q13315 1/20 0.36
KMT2A Q03164 3/20 0.36
MEN1 O00255 1/20 0.36
MITF O75030 1/20 0.36
STS P08842 1/20 0.36
MAP4K4 O95819 1/20 0.35
VEGFA P15692 1/20 0.35
EGLN1 Q9GZT9 1/20 0.35
CKS1B P61024 1/20 0.34
SKP1 P63208 1/20 0.34
SKP2 Q13309 1/20 0.34
GPR119 Q8TDV5 2/20 0.34
MET P08581 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5539813 1.00 ALDH1A1 (0.42) ALDH1A1LMNAMAPTPOLBKCNH2
SCHEMBL6010609 0.89 ALDH1A1 (0.43) ALDH1A1LMNAMAPTPOLBKCNH2
SCHEMBL5541421 0.89 ALDH1A1 (0.43) ALDH1A1LMNAMAPTPOLBKCNH2
SCHEMBL6010636 0.89 ALDH1A1 (0.43) ALDH1A1LMNAMAPTPOLBKCNH2
SCHEMBL5543012 0.88 MAPT (0.38) ALDH1A1LMNAMAPTKMT2AMEN1
SCHEMBL5542523 0.87 ALDH1A1 (0.41) ALDH1A1LMNAMAPTPOLBKCNH2
SCHEMBL5546006 0.86 LMNA (0.46) ALDH1A1LMNAMAPTHTTKMT2A
SCHEMBL5546002 0.86 LMNA (0.46) ALDH1A1LMNAMAPTHTTKMT2A
SCHEMBL5542233 0.86 MEN1 (0.41) ALDH1A1LMNAMAPTPOLBKCNH2
SCHEMBL5540333 0.85 DRD2 (0.46) ALDH1A1LMNAMAPTPOLBHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 ALDH1A1 355/4885LMNA 4152/4885MAPT 4117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.